awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q35776264-90E7F08F-102A-43D5-BFDA-18980C7A5B17
Q35776264-90E7F08F-102A-43D5-BFDA-18980C7A5B17
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35776264-90E7F08F-102A-43D5-BFDA-18980C7A5B17
Sorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO).
P2860
Q35776264-90E7F08F-102A-43D5-BFDA-18980C7A5B17
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35776264-90E7F08F-102A-43D5-BFDA-18980C7A5B17
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
70a30c2cf69c65a2f1e2238c1b0eba11ecbb8bcf
P2860
Inhibition of MAP kinase kinase causes morphological reversion and dissociation between soft agar growth and in vivo tumorigenesis in angiosarcoma cells.